Light Chain Bioscience
https://www.lightchainbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Light Chain Bioscience
Time To Shop? SK Sees ‘Biggest Opportunity’ For Biotech Investment
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
Enanta’s Path Forward Uncertain After RSV Failure
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
How Paxlovid Approval May Influence China's Pandemic Policies
In a surprise move, China has conditionally approved Pfizer’s oral COVID-19 antiviral Paxlovid, a development that may have far-reaching consequences for the country's pandemic policies and domestic drug developers.
Finance Watch: Prepare For September IPOs To Rebound From August Slowdown
Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- NovImmune SA